FDA Approved: EPYSQLI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approves Teva's supplemental application for EPYSQLI (eculizumab-aagh), a biosimilar to eculizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome
• Generalized Myasthenia Gravis
• Neuromyelitis Optica Spectrum Disorder
• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• EPYSQLI (eculizumab-aagh)

Snippet

SUPPL AP for EPYSQLI (ECULIZUMAB-AAGH)